Multiple Myeloma CAR T-Cell Therapy Achieves Response in 73% Patients Multiple Myeloma CAR T-Cell Therapy Achieves Response in 73% of Patients clinicalomicsprowebdirectory Scroll Up MORE CONTENT We use cookies to give you a better experience on clinicalomics.com. By continuing to use our site, you are agreeing to the use of cookies as set in our […]
Read More
Smoldering multiple myeloma: Early detection and intervention approaches by Dr. Mark Bustoros Mark Bustoros, MD provides an update on the research of early detection of multiple myeloma and intervention approaches that have the potential to greatly improve outcomes for multiple myeloma patients.
Read More
PLEIADES: Daratumumab combinations for multiple myeloma Dr Ajai Chari talks to ecancer at the International Myeloma Workshop 2019 about the PLEIADES studies. The studies look at daratumumab in combination with a variety of standard multiple myeloma treatment regimens. Dr Chari outlines some of the data from this trial, as well as any toxicities. Sign up […]
Read More
Steba Biotech receives FDA Orphan Drug Designation for Padeliporfin ImPACT in Upper Tract … Designation confers advantages including marketing exclusivity and tax credits Padeliporfin ImPACT pivotal Phase 3 trial in UTUC to start end Q1 2021 LUXEMBOURG, March 08, 2021 (GLOBE NEWSWIRE) — Steba Biotech, the IMmune Photo Activate Cancer Treatment (IMPACT) specialist today announces the […]
Read More
Third of patients with rare cancer initially misdiagnosed Third of patients with rare cancer initially misdiagnosed | NL Times Skip to main content Main navigation Published at Mon, 08 Mar 2021 08:15:00 +0000
Read More
Colon cancer screenings: ‘The only wrong option is to do nothing,’ doctor says March is Colorectal Cancer Awareness Month, and doctors want the public to know about the importance of screening. Colorectal cancer is the second-leading cause of cancer death in the U.S. for men and women combined. “The five-year survival rate for colorectal cancer […]
Read More
New CAR T-Cell therapy extends remission in heavily relapsed multiple myeloma patients IMAGE: A new type of CAR T-cell therapy more than triples the expected length of remission for multiple myeloma patients who have relapsed several times, according to an international clinical… view more Credit: UT Southwestern Medical Center DALLAS – March 8, 2021 – A […]
Read More
Expert Says CAR T-Cell Therapies Could Make Cancer a Chronic Disease In a recent interview with Pharmacy Times, Lee Greenberger, PhD, chief medical officer of the Leukemia and Lymphoma Society, said the development of chimeric antigen receptor (CAR) T-cell therapies is a major step for the treatment of some cancers. In a recent interview with […]
Read More
Cancer Care From the COVID-19 Frontlines: “Flying by the Seat of Our Pants” In early March 2020, the Association of Community Cancer Centers (ACCC) was among the last medical groups to hold its in-person meeting before the nation went into lockdown for COVID-19. And on March 1, 2021, a panel of experts shared a year’s […]
Read More
Go for cancer screening tests, SP tells women Superintendent of Police B. Rajakumari on Sunday urged middle-aged women to go for cancer screening tests immediately without any hesitation since the dreaded disease was curable when it was in early stages. She formally launched a two-day cancer screening camp organised by the Rotary Club Central-Vizianagaram. She […]
Read More